Assessment of New Molecular Entities Approved for Cancer Treatment in 2020

This cross-sectional study of all hematology/oncology drugs approved by the US Food and Drug Administration in 2020 assesses the functioning of the drug approval process following disruptions related to the COVID-19 pandemic.

Detalles Bibliográficos
Autores principales: Smith, Claire E. P., Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164099/
https://www.ncbi.nlm.nih.gov/pubmed/34047795
http://dx.doi.org/10.1001/jamanetworkopen.2021.12558
Descripción
Sumario:This cross-sectional study of all hematology/oncology drugs approved by the US Food and Drug Administration in 2020 assesses the functioning of the drug approval process following disruptions related to the COVID-19 pandemic.

Ejemplares similares